CombinatoRx signs anticancer screening deal with Novartis
This article was originally published in Scrip
Executive Summary
CombinatoRx has signed a $62 million deal with Novartis to screen a library of compounds to discover new anticancer combinations. The firms will examine combination effects in cell lines across a broad spectrum of cancers and explore differences in response by cancer type.